PDA Announces 2020 Drug Delivery Innovation Award Winners 9 October, 2020

Bethesda, Md., – The Parenteral Drug Association (PDA) announced the winners of the 2020 PDA Drug Delivery Innovation Awards at the 2020 PDA Universe of Pre-Filled Syringes and Injection Devices, Oct. 5-8, a virtual event. Awardees were recognized for their technical innovations in advancing the field of bio/pharmaceutical delivery devices.

The Innovation Award is presented to UCB Pharma for its presentation of Product Innovation through a Portfolio of Patient-Centric Self-Injection Devices for Certolizumab Pegol, submitted by Serkan Oray and David Harrison.

The CIMZIA ava electromechanical device (e-Device) is the first reusable device of its nature available for use with biologic treatment in rheumatology and dermatology. The inclusion of enhanced functions, such as on-screen instructions, an injection log and injection date notifications have not previously been included in a biologic self-injection device.

The Partnership Innovation Award is presented to SCHOTT Schweiz AG and CSL Behring for bringing a PFS immunoglobin drug successfully to the market, submitted by Tom Van Ginneken from SCHOTT and Frank Bamberg from CSL Behring.

Due to the collaboration between CSL and SCHOTT, CSL Behring was able to bring the first and only pre-filled Ig syringe is to the market. This syringe provides easier and more convenient drug administration process, reducing the risk for medical errors during manual vial-syringe preparation.

“I want to congratulate the companies and individuals that won the 2020 PDA Drug Delivery Innovation Awards and all the companies that were considered for this award,” said Richard Johnson, PDA President & CEO. “PDA launched these awards in 2019, and already we have seen growing interest in and prestige of the awards. We had an exceptional field of nominees this year. We look forward to the continued growth and visibility of these important awards.”


Media Inquiries

Walt Morris
Email address
[email protected]
Phone Number
301-656-5900, x. 148